Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yesterday. Bicycle Therapeutics put out a tweet saying " It’s an honor to be awarded Quoted Company of the Year by @businessweekly
! Thank you for recognizing our efforts to develop potentially life-changing medicines for patients around the world."
https://twitter.com/Bicycle_tx/status/1703787566812573706?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet
Good for them.
Why are they showing 1.8p to sell when it's 1.9p in reality ?
Got it!
Thanks 😊
It will move when the buys v sells changes
Most shares have periods of time (sometimes hours) where there is no visible change
Actually ignore my note, just seen some movement. Must have been my servers.
How comes the stock price is not moving? Does it not trade on Mondays?
That would be tremendous
Interesting to note HEMO today: A 240% premium has been paid to buy in to the business. The same could quite easily happen here. The HNWI buy ins at Sareum a couple of years ago boosted the share price significantly. As I mentioned last week Eli Lilly announced back in June that it planned to acquire a small bio, Sigilon, for $34.6 million. Sigilon’s stock jumped over 600%....
Good luck, Brighty
Hopefully more to come
A very nice Summary Acker
Thanks
L
Dropping the bid to 1.83 today and closing only 2.5% down. Surely gonna have movement next week. Will it be down again or we gonna see it move to about 2.5p again n back down. To the watching eye seems like they have rinsed the 2.3p to 1.9p cylce dry.
That large buy was greater than all the trades both on the buying and sold today. Seems like if ya want over £6k of these then the mms have work to do.
Thanks Brighty and Laura! Certainly a very interesting stock to watch as well as hold.
Thankyou Kidlington
I saw that last min buy ....intresting
Sienna found it by scanning thru the clinical trials website
Hit n miss I know
Daily Mail article August 2023
GlaxoSmithKline has begun using AI to make its medical treatments more personalised for individual patients
These recruitment efforts are often the longest part of the drug development process, but GSK said that using AI has allowed it to analyse massive quantities of data, making some parts of the clinical trial procedure up to five times faster.
AI has also been found to be useful for increasing the chances of a new medicine being successful in treating patients
From PYC website regarding PYC A.I applications
Personalised Dosing Tool Development
Data Identification
Identified public domain data on treatment of prostate cancer using docetaxel for 400+ patients from the comparator arm of a clinical tria
AI & Machine Learning
Applied AI techniques such as neural networks and other machine learning approaches to identify key factors linking dose, toxicity and efficacy
Web-Based Tool
Developed a web-based tool that could, if approved, form the basis of a decision support system for clinicians treating patients with prostate cancer to help reduce cost of toxicity and improve outcomes for patients
AB, in answer to your question what I would say is that PYC could achieve 20p a share in the next 12 - 18 months (at least) - which will still only be a Mcap of £27 Million. That's miniscule in this sector but would represent a x 10 multibag from the current share price. That’s why many are invested in PYC as the facts speak for themselves. i.e. PYC went from 1.3p to 4.2p in one day and then the next day it went to 10p and then as high as 32p intra-day before closing at 17.1p. That happened in 5 trading days back in 2017. OK there have been placings since then so the jump to 32p a share isn't (probably) going to happen in 5 days again. However, a few more contract gains and we will most likely be back at the 52 week high of 6.60p, or x 3 of our current share price. BUT as you can see that could just be the start of some meteoric rises for PYC on the back of Dr Peter Sargent joining PYC as Chief Operating Officer and the deals he could be bringing to the table. It’s also worth doing your research on the transactions happening in our sector, both big and small.e.g. On June 29, Eli Lilly announced it planned to acquire a small bio, Sigilon, for $34.6 million. Sigilon’s stock jumped over 600%. On June 26, Shionogi announced its plans to acquire a small company, Qpex Bio, for $100 million upfront, with potential for additional payments. These are not big deals in our sector but represent the kind of money being paid for innovative companies in our space. PYC falls in to this category. That's what is causing the excitement here and also what has happened to the share price in the past. i.e. 1.4p to 32p in 5 days....
Good luck, Brighty
Just gone through
Thanks Siennaj and Acker. I am also sympathetic to the idea that it’s a growth area of AI. Also I do think that the contracts are key in this game as well as delivering on those contracts.
What’s the price potential do you think in the coming months / years?
Ab201
The company is in an area of business which has tremendous growth potential.
As the contracts accumulate so does the reputation of the company.
The company can benefit from access to EU funding which will open new and exciting doors.
The company continues to strengthen its skill base which demonstrates confidence in moving forwards
IMO the current share price does not match the potential of the company
Hope this helps
Acker
Ab. It's a strong buy because the market cap is ridiculously low. Some guy has recently taken 3.3% of the company. They are renewing contracts with existing clients and new contracts with new clients and there is something going on with Artificial intelligence. I really don't understand the science but if you scroll thru Kidlington and Laura's posts you will have a good idea why it's a strong buy
What’s the potential for this stock? Also, why a strong buy in your view?
Kidlington. How did u track this company down?
I wonder if this is the company which recently gave PYC a £125k deal?
NuCana PLC, based in UK.
https://www.nucana.com/pipeline.html
https://clinicaltrials.gov/study/NCT05714553?locStr=UK&country=United%20Kingdom&distance=50&aggFilters=phase:0%201&limit=100&page=1&rank=52
time lines appear to fit? NU3373 also appears to be their lead asset as mentioned in the RNS??
Thoughts.